Following on from last year’s successful meeting, the 3rd RNA- Targeted Drug Discovery returns this December to unite 100+ key opinion leaders with expert insights for a unique, industry focussed and dedicated forum, accelerating the progression of RNA targeted drugs as a potential therapeutic approach.
This year, 25 speakers will share their specialist insights and latest data to this dedicated RNA community. From updates of Roche’s splicing modifier, to Arrakis announcing proprietary technology for RNA imaging, this is an unrivalled opportunity to hear first-hand from true RNA experts.
Speakers include Katie Warner, Vice President of RNA Biology & Co-Founder, Ribometrix, Melissa Moore, CSO, Moderna; Matthew Disney, Professor, Department of Chemistry & Neuroscience, Scripps Research Institute; Jennifer Petter, Founder & CSO, Arrakis Therapeutics; Simon Xi, Chief Executive Officer, Rgenta Therapeutics; Marcel Blommers, CSO, Saverna Therapeutics and many more.
“I am looking forward to the information exchange, mostly on the technical ends. What experimental details make the most difference in the hands of actual researchers (as opposed to what is written in papers),” says Gabe Sholder, Senior Scientist, Abbvie and expert speaker at this year’s 3rd RNA- Targeted Drug Discovery.
With surging levels of interest in the meeting’s workshops in the previous two editions, this next iteration also boasts a pre-conference workshop day featuring three online interactive workshops. Delegates will delve into RNA Modelling: Secondary & Tertiarty Structure of RNA; Harnessing Advanced Screening Approaches for RNA Targeting Small Molecule Lead Discovery; and Discovering Cross Learnings Between RNA-Targeted Small Molecule & mRNA Delivery Vehicle Development – all lead by pioneers of the RNA field such as Melissa Moore (Moderna), Katie Warner (Ribometrix) and Travis Wager (Rgenta).
This year’s event will be hosted on a bespoke digital platform to ensure the safety of all speakers and attending delegates. The platform has been specifically designed to not only allow for the live streaming of all presentations, but also to maximize delegates’ opportunities to network through dedicated speed networking sessions, live Q&As with speakers that are sure to spark lively discussions, and an instant messaging platform for private or group messaging throughout the summit.
With less than 6 weeks to go until the meeting, the 100+ strong delegate list is continuing to grow at speed. Companies in the ‘room’ so far include Merck, Biogen, Takeda, Pfizer, Johnson & Johnson, Vertex, Skyhawk Therapeutics and many more. They’ll all be joining the discussion to uncover the enigmas of RNA structure and function, learn how to streamline discovery and development of bioactive small molecule compounds and discover how pre-clinical proof of concepts will drive the field forward towards translation into clinical development.
To find out more about this event, view the full event guide here or visit www.rna-drugdiscovery.com.
Don’t miss out! Limited Passes Remain – secure your place here. Group discounts available.
Contact
General Enquiries & Registration Assistance
Flo Perkins
Delegate Acquisition Manager
Hanson Wade
(+1) 617 455 4188
info@hansonwade.com
Partnership Opportunities
Jacob Roberts-Kendall
Partnerships Director
Hanson Wade
(+1) 617 455 4188
sponsor@hasnonwade.com